Our results suggested that the serum levels of FGF21 may be related to obesity or hyperglycemia in patients with PTC, and that FGF21 promotes tumor progression via upregulation of the FGFR signaling axis, including phosphorylation of AKT and ERK. Here, AKT1 is linked to obesity disorder.